Ceftriaxone Reduces Inflammation in a Mouse Model of Multiple Sclerosis
Author Information
Author(s): Melzer Nico, Meuth Sven G., Torres-Salazar Delany, Bittner Stefan, Zozulya Alla L., Weidenfeller Christian, Kotsiari Alexandra, Stangel Martin, Fahlke Christoph, Wiendl Heinz
Primary Institution: Department of Neurology, University of Würzburg, Würzburg, Germany
Hypothesis
Can ceftriaxone, a β-lactam antibiotic, reduce excitotoxic inflammatory damage in a mouse model of multiple sclerosis?
Conclusion
Ceftriaxone treatment significantly reduces the severity and progression of disease in a mouse model of multiple sclerosis by impairing T cell activation and migration into the CNS.
Supporting Evidence
- Ceftriaxone significantly delayed the maximum disease score in treated mice.
- Mice treated with ceftriaxone showed a lower residual score compared to controls.
- Ceftriaxone treatment reduced T cell migration into the CNS.
- Ceftriaxone did not affect EAAT2 protein expression levels in the brain.
- Ceftriaxone treatment preserved its clinical effects even in the presence of an EAAT2 inhibitor.
Takeaway
Ceftriaxone, an antibiotic, helps mice with a disease similar to multiple sclerosis by stopping harmful immune cells from causing damage in the brain.
Methodology
Mice were immunized with MOG35–55 to induce EAE and treated with ceftriaxone, with clinical scores assessed over time.
Potential Biases
Potential bias in the interpretation of results due to the use of a single animal model.
Limitations
The study primarily focuses on a mouse model, which may not fully replicate human disease.
Participant Demographics
C57BL/6 mice, aged 6-8 weeks.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website